Hormonal
Switching patients from DPP-4 inhibitors to GLP-1 receptor agonists improves glycemic control and weight loss, although it may transiently increase gastrointestinal adverse events.
If you are taking a DPP-4 inhibitor (like sitagliptin) and your blood sugar or weight goals aren't being met, switching to a GLP-1 receptor agonist (like exenatide or liraglutide) is a recommended next step. This switch typically leads to better blood sugar control and more weight loss. You may experience some temporary stomach issues, but these often subside.
A few studies have evaluated switching patients from DPP-4 inhibitors to a GLP-1RA and, as expected, improved glycemic control and weight loss are seen following the switch.
Why this rating
Based on specific switch trials (Wysham, Pratley, Bailey) cited in the review.
Source
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Matthew P. Gilbert et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00178
More from this paper
- GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to DPP-4 inhibitors in patients with type 2 diabetes, despite a higher incidence of gastrointestinal side effects.Strong
- Combining a GLP-1 receptor agonist with a DPP-4 inhibitor (add-on therapy) provides better glycemic control than switching, without a significant increase in adverse events, contrary to theoretical predictions of antagonism.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →